AstraZeneca Diprivan Pediatric ICU Sedation Safety Study Requested By FDA
AstraZeneca is planning an additional study of Diprivan for pediatric ICU sedation after finding an increased rate of mortality with the injectable anesthetic in a trial seeking the indication.
You may also be interested in...
AstraZeneca must issue a "Dear Healthcare Provider" letter clarifying misleading information regarding generic propofol found in its promotional materials for the anesthetic Diprivan, an FDA warning letter states.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials